Outlier in a BE study [Outliers]

posted by riteshsrmc  – India, 2014-01-16 13:44 (4186 d 08:18 ago) – Posting: # 12177
Views: 11,246

Hi Auditor,

By the way to which agency you are filing the product? Agreed with Dan! EMEA has clearly defined the situation in guidance. I would suggest you to look at FDA perspective as well, if you are filing to FDA. FDA does not encourage redosing to handle outliers subjects incase of non-replicate design study wherein you may carry out redosing incase of replicate design. You should be clear they way agency look at the data with or without outliers.

Complete thread:

UA Flag
Activity
 Admin contact
23,426 posts in 4,929 threads, 1,681 registered users;
38 visitors (0 registered, 38 guests [including 24 identified bots]).
Forum time: 23:02 CEST (Europe/Vienna)

You can do one of two things; just shut up,
which is something I don’t find easy,
or learn an awful lot very fast,
which is what I tried to do.    Jane Fonda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5